Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia

Clinical Advances in Hematology and Oncology

Volumn 11, Issue 9, 2013, Pages 571-577

  Walter, Roland B ^a   Taylor, Lenise R ^b   Gardner, Kelda M ^b   Shannon Dorcy, Kathleen ^a   Vaughn, Jennifer E ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Early hospital discharge; Health care cost; Intensive chemotherapy; Outpatient management; Quality of life

Indexed keywords

ANTIBIOTIC AGENT; CYTARABINE; DOXORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); ECONOMIC ASPECT; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; LEUKEMIA RELAPSE; NURSING; OUTPATIENT CARE; PROPHYLAXIS; QUALITY OF LIFE; SALVAGE THERAPY; SEPTICEMIA;

ADULT; AMBULATORY CARE; HUMANS; LEUKEMIA, MYELOID, ACUTE; SALVAGE THERAPY;

EID: 84884409488     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Strat- ton Lecture, 1982). Blood. 1983;62(1):1-13.
3. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051-1062.
4. Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894-1907.
5. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
6. Burnett A, Wetzler M, Lowenberg B. Terapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
7. Ferrara F, Schifer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381(9865):484-495.
8. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
9. Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia (AML) given "intensive" induction regimens: a report from the Southwest Oncology Group (SWOG) and MD Anderson Cancer Center (MDA) [published online ahead of print June 13, 2013]. Leukemia. 2013. doi:10.1038/leu.2013.176.
10. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophy-laxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs. 2012;72(5):685-704.
11. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-1098.
12. Giles FJ, Borthakur G, Ravandi F, et al. Te haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624-627.
13. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000-2008.
14. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-4423.
15. Estey E. Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol. 2001;38(4 suppl 10):32-37.
16. Eisele L, Günther F, Ebeling P, Nabring J, Dührsen U, Dürig J. Outpatient management of acute myeloid leukemia after intensive consolidation chemotherapy is feasible and reduces hospital treatment costs. Onkologie. 2010;33(12):658-664.
17. Girmenia C, Alimena G, Latagliata R, et al. Out-patient management of acute myeloid leukemia after consolidation chemotherapy. Role of a hematologic emergency unit. Haematologica. 1999;84(9):814-819.
18. Allan DS, Buckstein R, Imrie KR. Outpatient supportive care following chemotherapy for acute myeloblastic leukemia. Leuk Lymphoma. 2001;42(3):339-346.
19. Sopko L, Sabty FA, Rimajova V, et al. Te feasibility of an early hospital discharge following chemotherapy for the acute myeloid leukemia. Bratisl Lek Listy. 2012;113(5):298-300.
20. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328-340.
21. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228-237.
22. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6(2):109-118.
23. Appelbaum FR, Rosenblum D, Arceci RJ, et al. End points to establish the efcacy of new agents in the treatment of acute leukemia. Blood. 2007;109(5):1810-1816.
24. Efcace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer. 2008;44(11):1497-1506.
25. Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev. 2004;30(3):237-247.
26. Kasteng F, Sobocki P, Svedman C, Lundkvist J. Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care. 2007;23(1):43-53.
27. Marie JP, Bisserbe S, Bouaziz C, Wdowick T, Zittoun R. [A program for medical use of information systems. Validity of calculation of direct costs for the initial treatment of acute myeloblastic leukemia]. Presse Med. 1992;21(29):1364-1368.
28. Stalfelt AM, Brodin H, Wadman B. Cost analysis of diferent phases of acute myeloid leukaemia. Leuk Res. 1994;18(10):783-790.
29. Kuse R, Colberg H, Marbe W, Kodalle O, Kalmar P, Lohfert C. Which factors render cost-covering lump-sum charging difcult for the treatment of patients with acute leukemias? Onkologie. 2001;24(3):292-294.
30. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. Te outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597-1603.
31. Katz LM, Howell JB, Doyle JJ, et al. Outcomes and charges of elderly patients with acute myeloid leukemia. Am J Hematol. 2006;81(11):850-857.
32. Fagnoni P, Limat S, Hintzy-Fein E, et al. [Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarifcation]. Bull Cancer. 2006;93(8):813-819.
33. Nerich V, Lioure B, Rave M, et al. Induction-related cost of patients with acute myeloid leukaemia in France. Int J Clin Pharm. 2011;33(2):191-199.
34. Leunis A, Blommestein HM, Huijgens PC, Blijlevens NMA, Jongen-Lavrencic M, Uyl-de Groot CA. Te costs of initial treatment for patients with acute myeloid leukemia in the Netherlands. Leuk Res. 2013;37(3):245-250.
35. Rosenthal MB. Nonpayment for performance? Medicare's new reimbursement rule. N Engl J Med. 2007;357(16):1573-1575.
36. Bucaneve G, Micozzi A, Menichetti F, et al. Levofoxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977-987.
37. Halim TY, Song KW, Barnett MJ, et al. Positive impact of selective outpatient management of high-risk acute myelogenous leukemia on the incidence of septice-mia. Ann Oncol. 2007;18(7):1246-1252.
38. Tennvall GR, Persson U, Nilsson B. Te economic costs of acute myeloid leukemia in Sweden. Int J Technol Assess Health Care. 1994;10(4):683-694.
39. Ruiz-Argüelles GJ, Apreza-Molina MG, Alemán-Hoey DD, Gómez-Almaguer D, Marín-López A, Mercado-Díaz L. Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. Eur J Haematol. 1995;54(1):18-20.
40. Gillis S, Dann EJ, Rund D. Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia. Am J Hematol. 1996;51(1):26-31.
41. Savoie ML, Nevil TJ, Song KW, et al. Shifting to outpatient management of acute myeloid leukemia: a prospective experience. Ann Oncol. 2006;17(5):763-768.
42. Møller T, Nielsen OJ, Welinder P, et al. Safe and feasible outpatient treatment following induction and consolidation chemotherapy for patients with acute leukaemia. Eur J Haematol. 2010;84(4):316-322.
43. Walter RB, Lee SJ, Gardner KM, et al. Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. Haematologica. 2011;96(6):914-917.
44. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915.
45. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. 2012;87(7):692-701.